- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
FDA Could OK Fall COVID Shots as Early as This Week
Updated shots you could use this fall to shield against COVID-19 infection may receive approval this week.
Two sources familiar with the issue told CNN that updated mRNA vaccines from Moderna and Pfizer that target a variant of the virus called KP.2 could be greenlit as early as this week. The news agency said the sources declined to be named because information around the timing of approval hasn’t yet been made public.
It’s not clear whether approval for Novavax’ non-mRNA shot, targeted to the JN.1 strain, would be approved simultaneously.
If approval does come this week, that would be a few weeks ahead of the timing for last fall’s shots, which were approved on Sept. 11.
The news comes as Americans are suffering through a summer surge of COVID cases — the highest seen since the summer of 2022, based on wastewater levels of virus tracked by the U.S. Centers for Disease Control and Prevention.
According to CDC data, the prevalent COVID variant is now KP.3.1.1, thought to make up 37% of cases over the past two weeks.
Still, experts note that although levels of severe disease have been rising, they remain much lower than those seen during the early years of the pandemic.
KP.3.1.1 and KP.2, which are both covered in the updated shots, are offshoots of JN.1. All are members of the Omicron family.
Both Moderna and Pfizer have said they have ample supplies of their updated COVID vaccines on hand, ready for shipment to stores soon after FDA approval. Novavax’ vaccine may take a bit longer to reach consumers, because its protein-based shot takes longer to manufacture than mRNA vaccines do.
In June, the CDC recommended that every American over the age of 6 months receive an updated COVID-19 shot along with the flu shot this year.
Should you get a dose of the current COVID vaccine, or wait for the updated shots?
Speaking with CNN, Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, said he’s getting both.
“Now is the time to get a dose with this surge,” he reasoned.
Osterholm recommends boosting your immunity now with the current vaccine during the summer’s uptick in cases, and getting the updated shot in about four months — the interval recommended by health officials.
More information
Find out more about the COVID vaccine at the Mayo Clinic.
SOURCE: CNN
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.